#1 Clinical Trials Search in Europe

Dolutegravir Sodium

This article examines the use of Dolutegravir Sodium, an antiretroviral medication, in clinical trials for the treatment of HIV. We’ll explore how researchers are investigating its effectiveness, safety profile, and potential benefits compared to other HIV treatments. The trials aim to better understand Dolutegravir’s role in managing HIV infections and improving patient outcomes.

Table of Contents

What is Dolutegravir?

Dolutegravir sodium, also known by its brand names Tivicay[1] or Dotilavir[2], is a powerful medication used in the treatment of Human Immunodeficiency Virus (HIV) infection. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs), which are considered some of the most effective medications for managing HIV.

Uses of Dolutegravir

Dolutegravir is primarily used to treat HIV-1 infection in adults and children. It can be used in various scenarios:

  • As part of initial treatment for people newly diagnosed with HIV[3]
  • To replace other HIV medications in people who have already achieved viral suppression (when the amount of HIV in the blood is very low)[4]
  • In combination with other antiretroviral drugs to maintain viral suppression[5]
  • For patients who have developed resistance to other HIV medications[6]

How Dolutegravir Works

Dolutegravir works by blocking an enzyme called integrase that HIV needs to multiply. By doing this, it helps prevent the virus from making copies of itself and infecting more cells in your body. This action helps to reduce the amount of HIV in your blood (known as viral load) and increase your CD4 cell count (a type of white blood cell that fights infection)[1].

Dosage and Administration

Dolutegravir is typically taken as a tablet once or twice daily, depending on your specific situation. The usual dose for adults is 50 mg once daily, but this can vary based on factors such as:

  • Whether you’re taking it for the first time or switching from another medication
  • If you’re also taking certain other medications
  • If you have resistance to other HIV medications

In some cases, such as when taken with certain tuberculosis medications, the dose may need to be increased to 50 mg twice daily[7]. Always follow your healthcare provider’s instructions regarding dosage.

Effectiveness of Dolutegravir

Clinical trials have shown that dolutegravir is highly effective in treating HIV. It has demonstrated good virological and immunological outcomes in both new patients and those who have been treated before[3]. In many cases, it has been shown to be non-inferior or even superior to other HIV medications in maintaining viral suppression[5].

Potential Side Effects

Like all medications, dolutegravir can cause side effects, although not everyone experiences them. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Sleep problems

More serious side effects are rare but can occur. These may include allergic reactions or liver problems. Always inform your healthcare provider of any side effects you experience[3].

Special Considerations

There are some special considerations when taking dolutegravir:

  • Drug interactions: Dolutegravir can interact with other medications, including some for tuberculosis. Your doctor will need to know all medications you’re taking[7].
  • Pregnancy: If you’re pregnant or planning to become pregnant, discuss this with your doctor. There have been concerns about potential birth defects when dolutegravir is taken early in pregnancy, although recent data suggest this risk may be lower than initially thought[5].
  • Liver disease: If you have liver problems, your doctor may need to monitor you more closely while taking dolutegravir.

Ongoing Research

Researchers continue to study dolutegravir to understand its long-term effects and explore new ways it can be used. Some ongoing areas of research include:

  • Using dolutegravir in two-drug regimens instead of the traditional three-drug combinations for HIV treatment[6]
  • Investigating its effectiveness in children and adolescents[7]
  • Studying its use in patients who also have tuberculosis[7]
  • Exploring its potential to reduce HIV-related immune activation[1]

These ongoing studies aim to further improve HIV treatment and potentially simplify medication regimens for people living with HIV.

Aspect Details
Drug Name Dolutegravir Sodium (also known as DTG)
Drug Class Integrase Strand Transfer Inhibitor (INSTI)
Main Use Treatment of HIV-1 infection
Dosage Forms Tablets (50mg), Dispersible tablets (10mg)
Administration Oral, typically once or twice daily
Key Study Objectives Efficacy, safety, pharmacokinetics, impact on viral load and CD4 count
Special Populations Studied Adults, children with HIV, patients with HIV-TB co-infection
Comparators in Trials Protease inhibitors, other antiretroviral regimens
Potential Side Effects Monitored Neuropsychiatric effects, weight changes, sleep disturbances
Additional Research Focus Impact on gut microbiota, pharmacogenetics, long-term tolerability

FAQ

  • What is Dolutegravir Sodium? Dolutegravir Sodium is an antiretroviral medication used to treat HIV infections. It belongs to a class of drugs called integrase inhibitors, which work by preventing the HIV virus from multiplying in the body.
  • How is Dolutegravir being studied in clinical trials? Dolutegravir is being studied in various ways, including its effectiveness as part of combination therapy, its use in different patient populations (adults and children), and its potential benefits when switching from other HIV medications.
  • What are some potential side effects of Dolutegravir? Some potential side effects being studied include neuropsychiatric effects (such as insomnia, depression, and anxiety), changes in weight, and impacts on sleep quality. Researchers are also monitoring for any other unexpected side effects.
  • How does Dolutegravir compare to other HIV treatments? Clinical trials are comparing Dolutegravir to other HIV treatments, particularly protease inhibitors. Researchers are looking at factors such as viral suppression, drug concentrations in the body, and overall tolerability.
  • What is the goal of these Dolutegravir clinical trials? The main goals are to determine Dolutegravir's effectiveness in treating HIV, understand its safety profile, identify any potential side effects, and explore how it might improve upon existing HIV treatments in terms of efficacy and patient quality of life.

Ongoing Clinical Trials on Dolutegravir Sodium

  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Reducing HIV Latent Reservoirs Using High Doses of Lamivudine, Maraviroc, and Dolutegravir Sodium for Patients with HIV Infection

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Dolutegravir and Lamivudine for Maintaining Viral Control in Children with HIV Aged 2 to Under 15 Years

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Triumeq (Abacavir Sulfate, Lamivudine, Dolutegravir Sodium) in Patients with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland The Netherlands Slovenia Spain Sweden

  • Study on the Effectiveness of Doravirine and Dolutegravir for People with HIV Switching Antiretroviral Therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Patients with Good Control and Neuropsychiatric Concerns

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +2

Glossary

  • Antiretroviral therapy (ART): A combination of medications used to treat HIV infection by suppressing the virus and slowing the progression of the disease.
  • Viral load: The amount of HIV virus in a person's blood. A lower viral load indicates better control of the infection.
  • CD4 count: A measure of the number of CD4 T cells in the blood, which helps assess the strength of the immune system in people with HIV.
  • Integrase inhibitor: A class of antiretroviral drugs that work by blocking the action of integrase, an enzyme the HIV virus needs to insert its genetic material into human cells.
  • Virological suppression: When antiretroviral therapy reduces a person's viral load to an undetectable level.
  • Pharmacokinetics: The study of how drugs move through the body, including how they are absorbed, distributed, metabolized, and eliminated.
  • Bioequivalence: When two medications have the same active ingredient and produce the same effect in the body.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Protocol-defined virological failure: When a patient's viral load increases above a certain level as defined by the study protocol, indicating that the treatment may not be effectively controlling the HIV infection.
  • Genotypic resistance testing: A test to identify genetic mutations in the HIV virus that may make it resistant to certain antiretroviral medications.

References

  1. https://clinicaltrials.gov/study/NCT02500446
  2. https://clinicaltrials.gov/study/NCT05168176
  3. https://clinicaltrials.gov/study/NCT01966822
  4. https://clinicaltrials.gov/study/NCT02499978
  5. https://clinicaltrials.gov/study/NCT04229290
  6. https://clinicaltrials.gov/study/NCT03683524
  7. https://clinicaltrials.gov/study/NCT04746547